Treatment of nevoid basal cell carcinoma syndrome: a case report

被引:1
|
作者
Seo, Dong-Uk [1 ]
Kim, Su-Gwan [1 ]
Oh, Ji-Su [1 ]
You, Jae-Seek [1 ]
机构
[1] Chosun Univ, Sch Dent, Dept Oral & Maxillofacial Surg, 303 Pilmun Daero, Gwangju 61452, South Korea
关键词
Basal cell nevus syndrome; Jaw cysts;
D O I
10.5125/jkaoms.2016.42.5.284
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin syndrome, is characterized by various embryological deformities and carcinoma formation. It is caused by PTCHI gene mutations and is autosomal dominantly inherited. Some of the main symptoms of NBCCS are multiple basal cell carcinomas, multiple keratocystic odontogenic tumors (KCOTs) of the mandible, hyperkeratosis of the palmar and plantar, skeletal deformity, calcification of the falx cerebri, and facial defomity. Recurrent KCOT is the main symptom of NBCCS and is present in approximately 90% of patients. In NBCCS, KCOTs typically occur in multiples. KCOTs can be detected in patients under the age of 10, and new and recurring cysts develop until approximately the age of 30. The postoperation recurrence rate is approximately 60%. This case report presents a 14-year-old female patient with a chief complaint of a cyst found in the maxilla and mandible. The patient was diagnosed with NBCCS, and following treatment of marsupialization and enucleation, the clinical results were satisfactory.
引用
收藏
页码:284 / 287
页数:4
相关论文
共 50 条
  • [31] Acquisition of Drug Resistance in Basal Cell Nevus Syndrome Tumors through Basal to Squamous Cell Carcinoma Transition
    Jussila, Anna R.
    Haensel, Daniel
    Gaddam, Sadhana
    Oro, Anthony E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2024, 144 (06) : 1368 - 1377.e6
  • [32] In Situ Melanoma in Collision With a Basal Cell Carcinoma in a Patient With Basal Cell Nevus Syndrome: Clinical and Dermoscopic Features
    Briatico, Giulia
    Moscarella, Elvira
    Ronchi, Andrea
    Procaccini, Enrico Maria
    Argenziano, Giuseppe
    DERMATOLOGY PRACTICAL & CONCEPTUAL, 2019, 9 (04): : 310 - 312
  • [33] Features of Basal Cell Carcinomas in Basal Cell Nevus Syndrome
    Tom, Wynnis L.
    Hurley, M. Yadira
    Oliver, Dana S.
    Shah, Maulik R.
    Bree, Alanna F.
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2011, 155A (09) : 2098 - 2104
  • [34] VISMODEGIB IN BASAL CELL CARCINOMA
    Amaria, R. N.
    Bowles, D. W.
    Lewis, K. D.
    Jimeno, A.
    DRUGS OF TODAY, 2012, 48 (07) : 459 - 467
  • [35] Nodular Basal Cell Carcinoma
    Morrell, Travis J.
    Chung, Grace Y.
    Calame, Antoanella
    JOURNAL OF THE DERMATOLOGY NURSES ASSOCIATION, 2015, 7 (05) : 293 - 295
  • [36] Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome
    Weiss, Glen J.
    Tibes, Raoul
    Blaydorn, Lisa
    Jameson, Gayle
    Downhour, Molly
    White, Erica
    Caro, Ivor
    Von Hoff, Daniel D.
    DERMATOLOGY REPORTS, 2011, 3 (03) : 125 - 127
  • [37] Pediatric basal cell carcinoma burden and management preferences in Gorlin syndrome: A survey study
    Neale, Holly
    Breneiser, Julie A.
    Hawryluk, Elena B.
    JAAD INTERNATIONAL, 2021, 5 : 49 - 51
  • [38] Basal cell carcinoma: Treatment options and prognosis, a scientific approach to a common malignancy
    Kuijpers D.I.M.
    Thissen M.R.T.M.
    Neumann M.H.A.
    American Journal of Clinical Dermatology, 2002, 3 (4) : 247 - 259
  • [39] Assessing Current Treatment Options for Patients With Severe/Advanced Basal Cell Carcinoma
    Weinstock, Martin A.
    Still, Joanne M.
    SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2011, 30 (04) : S10 - S13
  • [40] Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors
    Fecher, Leslie A.
    Sharfman, William H.
    BIOLOGICS-TARGETS & THERAPY, 2015, 9 : 129 - 140